##### 



[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
 Exhibit 10.110
  
 Re:
    
    Amendment No. 4 to the Data Transfer, Clinical Trial and Market Supply Agreement, dated as of
January 27, 2000
   1.
    
    The parties hereby agree to replace Section 2 of Amendment No. 3 to the
Agreement dated July 26, 2005 in its entirety as follows:The parties hereby agree that InterMunes obligation to purchase [ * ]of [ * ]of the
PRODUCT for [ * ]pursuant to Section 3.2.1 of the Agreement shall be [ * ]for such [ *
]without liability or penalty to InterMune with regard to the aforementioned [ * ];
provided, however that InterMune shall also pay to BI Austria a sum of Three Million
Three Hundred Ninety-Four Thousand Fifty Euros (3,394,050) for such [ * ]before the
end of 2006 as consideration for a price reduction per vial for purchases of PRODUCT by
InterMune in 2007 and 2008 (as set forth in detail in Section 4.1 of the Agreement).
The parties further hereby agree that with respect to such [ * ]that InterMune is
required[ * ]to purchase in [ * ]pursuant to Section 3.2.1 of the Agreement after
giving effect to the modification thereto as set forth in this Section 3 of this
Amendment, [ * ]will be produced by BI Austria in the [ * ]for delivery to InterMune
in the [ * ]and [ * ]will have [ * ]of in the [ * ]of [ * ].2.
    
    The Agreement is hereby amended by adding at the end of Section 4.1 the following:




---



##### 



Notwithstanding the foregoing, the per unit price (i.e., [ * ]price) to be paid by
InterMune for purchases of PRODUCT for each of the [ * ]shall be [ * ]the amount
derived by [ * ]Euros ([ * ]) by the total number of units (i.e., number [ * ]) of
PRODUCT purchased and received by InterMune for each [ * ](Per Unit [ * ]
Calculation).The Parties understand and agree that since purchases of PRODUCT and payment therefor
will occur periodically throughout the course of each [ * ], the Parties will cooperate
with one another in good faith to first estimate the total number of units of PRODUCT
InterMune will purchase and receive for [ * ]at the [ * ](Projected Units). The
Parties will use the Projected Units in the Per Unit [ * ]Calculation for purposes of
BI Austrias charges and invoices to InterMune and InterMunes payments for PRODUCTS
purchased during the course of the [ * ]. At the [ * ], a reconciliation will be
conducted by the Parties by comparing the Per Unit [ * ]Calculation using the Projected
Units with the Per Unit [ * ]Calculation using the total number of units of PRODUCTS
actually purchased and received by InterMune for the [ * ]. If InterMune has underpaid
because the total number of units of PRODUCTS actually purchased and received by
InterMune for the [ * ]is more than the Projected Units, then InterMune will pay to BI
Austria the amount of the difference. If InterMune has overpaid because the total
number of units of Products actually purchased and received by InterMune for the [ * ]
is less than the Projected Units, then BI Austria shall reimburse InterMune for the
amount of such overpayment.By way of example, assume that the Parties estimate [ * ]. [ * ], BI Austria would be
charging InterMune a per unit price for PRODUCTS purchased by InterMune that will take
into account a per unit [ * ]of [ * ] (derived by [ * ]). Assume further that at [ *
], InterMune has actually purchased [ * ]of PRODUCT in total such that the [ * ]price
InterMune owes BI Austria for [ * ]should have been [ * ](i.e., derived by [ * ])
rather than [ * ]. Consequently, InterMune would have been overpaying BI Austria for
the purchases of PRODUCT [ * ]and BI Austria would be obligated to reimburse InterMune
the amount for which InterMune overpaid.[ * ], in the event InterMune does not purchase [ * ]as defined in the second
(2nd) paragraph of Section 3.2.1 of this Agreement and the total number of
units of PRODUCT actually purchased and received by InterMune [ * ]does not result in [
* ]equal to [ * ]Euros ([ * ]), then InterMune shall be entitled to apply the
difference between [ * ]Euros ([ * ]) and the [ * ]for the total number of units of
PRODUCTS purchased and received by InterMune [ * ]to offset that amount InterMune is
required to pay to BI Austria under the second (2nd) paragraph of Section
3.2.1 as a result of [ * ](i.e., that amount equal to [ * ]and that amount of PRODUCT
actually purchased and received by InterMune [ * ]).
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.




---



##### 



Sincerely,InterMune, Inc.
    
    
    
    Accepted and Agreed:Boehringer Ingelheim Austria GmbHBy:
    
    /s/ Daniel G. WelchDaniel G. Welch,President and Chief Executive Officer
    
    
    
    By:
    
    /s/ Kurt Konopitzky

Dr. Kurt KonopitzkyHead Division BiopharmaceuticalsDate:
    
    December 21, 2006
    
    
    
    
    
    DivisionDate:
    
    December 22, 2006Boehringer Ingelheim Austria GmbHBy:
    
    /s/ Monika Henninger

Dr. Monika HenningerHead, Customer Relations & ProjectsDate:
    
    December 22, 2006
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.